Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Sep 18, 2023

SELL
$0.13 - $76.84 $2,979 - $1.76 Million
-22,920 Reduced 81.51%
5,200 $369,000
Q2 2022

Sep 18, 2023

SELL
$72.62 - $79.98 $31,952 - $35,191
-440 Reduced 1.54%
28,120 $2.17 Million
Q4 2021

Sep 18, 2023

SELL
$53.63 - $62.52 $27,619 - $32,197
-515 Reduced 1.77%
28,560 $1.78 Million
Q3 2021

Sep 18, 2023

BUY
$59.17 - $69.31 $1.72 Million - $2.02 Million
29,075 New
29,075 $1.72 Million
Q2 2021

Aug 11, 2021

BUY
$61.91 - $67.42 $8,667 - $9,438
140 Added 0.57%
24,750 $1.65 Million
Q1 2021

May 04, 2021

BUY
$59.34 - $66.74 $9,791 - $11,012
165 Added 0.67%
24,610 $1.55 Million
Q4 2020

Feb 05, 2021

SELL
$57.74 - $65.43 $1,154 - $1,308
-20 Reduced 0.08%
24,445 $1.52 Million
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $270,810 - $316,604
-4,940 Reduced 16.8%
24,465 $1.44 Million
Q1 2020

May 06, 2020

SELL
$46.4 - $67.43 $510,168 - $741,392
-10,995 Reduced 27.22%
29,405 $1.64 Million
Q4 2019

Feb 07, 2020

SELL
$49.21 - $64.19 $80,458 - $104,950
-1,635 Reduced 3.89%
40,400 $2.59 Million
Q3 2019

Oct 28, 2019

BUY
$42.77 - $50.71 $86,181 - $102,180
2,015 Added 5.03%
42,035 $2.13 Million
Q2 2019

Aug 07, 2019

BUY
$44.62 - $49.34 $37,034 - $40,952
830 Added 2.12%
40,020 $1.82 Million
Q1 2019

May 06, 2019

SELL
$45.12 - $53.8 $126,336 - $150,640
-2,800 Reduced 6.67%
39,190 $1.87 Million
Q4 2018

Feb 01, 2019

BUY
$48.76 - $63.23 $82,892 - $107,491
1,700 Added 4.22%
41,990 $2.18 Million
Q3 2018

Nov 08, 2018

SELL
$55.19 - $62.25 $44,152 - $49,800
-800 Reduced 1.95%
40,290 $2.5 Million
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $2.27 Million - $2.62 Million
41,090
41,090 $2.62 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Washington Capital Management Inc Portfolio

Follow Washington Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Washington Capital Management Inc with notifications on news.